Pharmacophore modeling, 3D-QSAR, and molecular docking study on naphthyridine derivatives as inhibitors of 3-phosphoinositide-dependent protein kinase-1

被引:4
作者
Kirubakaran, Palani [1 ]
Muthusamy, Karthikeyan [1 ]
Singh, Kh Dhanachandra [1 ]
Nagamani, Selvaraman [1 ]
机构
[1] Alagappa Univ, Dept Bioinformat, Karaikkudi 630004, Tamil Nadu, India
关键词
3-Phosphoinositide-dependent protein kinase-1; PDK1; Pharmacophore mapping; 3D-QSAR; External validation; Molecular docking; PDK1; PHOSPHORYLATION; ACTIVATION; QSAR; PATHWAY; PHASE; IDENTIFICATION; DISCOVERY; POTENT; SERUM;
D O I
10.1007/s00044-012-0383-5
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The 3-phosphoinositide-dependent protein kinase-1 (PDK1) is an imminent target for discovering novel anticancer drugs. In order to understand the structure-activity correlation of naphthyridine-based PDK-1 inhibitors, we have carried out a combined pharmacophore, three-dimensional quantitative structure-activity relationship (3D-QSAR), and molecular docking studies. The study has resulted in six point pharmacophore models with four hydrogen bond acceptors (A), one hydrogen bond donor (D), and one aromatic ring (R) are used to derive a predictive atom-based 3D-QSAR model. The generated 3D-QSAR model shows that the alignment has good correlation coefficient for the training set compounds which comprises the values of R (2) = 0.96, SD = 0.2, and F = 198.2. Test set compounds shows Q (2) = 0.84, RMSE = 0.56, and Pearson-R = 0.84. The external validation was carried out to validate the predicted QSAR model which shows good predictive power of = 0.83 and k = 1.01, respectively. The external validation results also confirm the fitness of the model. The results indicated that, atom-based 3D-QSAR models and further modifications in PDK1 inhibitors via pharmacophore hypothesis are rational for the prediction of the activity of new inhibitors in prospect of drug design.
引用
收藏
页码:3812 / 3822
页数:11
相关论文
共 44 条
[1]   Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B alpha [J].
Alessi, DR ;
James, SR ;
Downes, CP ;
Holmes, AB ;
Gaffney, PRJ ;
Reese, CB ;
Cohen, P .
CURRENT BIOLOGY, 1997, 7 (04) :261-269
[2]   3-phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase [J].
Alessi, DR ;
Deak, M ;
Casamayor, A ;
Caudwell, FB ;
Morrice, N ;
Norman, DG ;
Gaffney, P ;
Reese, CB ;
MacDougall, CN ;
Harbison, D ;
Ashworth, A ;
Bownes, M .
CURRENT BIOLOGY, 1997, 7 (10) :776-789
[3]   Small-Molecule Inhibitors of Phosphatidylinositol 3-Kinase/Akt Signaling Inhibit Wnt/β-Catenin Pathway Cross-Talk and Suppress Medulloblastoma Growth [J].
Baryawno, Ninib ;
Sveinbjornsson, Baldur ;
Eksborg, Staffan ;
Chen, Ching-Shih ;
Kogner, Per ;
Johnsen, John Inge .
CANCER RESEARCH, 2010, 70 (01) :266-276
[4]   Development of CoMFA and CoMSIA models of cytotoxicity data of anti-HIV-1-phenylamino-1H-imidazole derivatives [J].
Basu, Arijit ;
Jasu, Kalsariya ;
Jayaprakash, Venkatesan ;
Mishra, Nibha ;
Ojha, P. ;
Bhattacharya, S. .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2009, 44 (06) :2400-2407
[5]   Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN+/- mice [J].
Bayascas, JR ;
Leslie, NR ;
Parsons, R ;
Fleming, S ;
Alessi, DR .
CURRENT BIOLOGY, 2005, 15 (20) :1839-1846
[6]   Intracellular signalling: PDK1 - a kinase at the hub of things [J].
Belham, C ;
Wu, SL ;
Avruch, J .
CURRENT BIOLOGY, 1999, 9 (03) :R93-R96
[7]   The Protein Data Bank [J].
Berman, HM ;
Westbrook, J ;
Feng, Z ;
Gilliland, G ;
Bhat, TN ;
Weissig, H ;
Shindyalov, IN ;
Bourne, PE .
NUCLEIC ACIDS RESEARCH, 2000, 28 (01) :235-242
[8]   Ten years of protein kinase B signalling: a hard Akt to follow [J].
Brazil, DP ;
Hemmings, BA .
TRENDS IN BIOCHEMICAL SCIENCES, 2001, 26 (11) :657-664
[9]   The Akt/PKB pathway: molecular target for cancer drug discovery [J].
Cheng, JQ ;
Lindsley, CW ;
Cheng, GZ ;
Yang, H ;
Nicosia, SV .
ONCOGENE, 2005, 24 (50) :7482-7492
[10]   Protein kinases - the major drug targets of the twenty-first century? [J].
Cohen, P .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (04) :309-315